Scientists Identify Biomarker for Advanced Prostate Cancer as Specific Androgen Receptor in Circulating Cancer Cells

Scientists Identify Biomarker for Advanced Prostate Cancer as Specific Androgen Receptor in Circulating Cancer Cells
Expression of the nuclear androgen-receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs) found in the blood of patients with advanced prostate cancer predicts the patients will fail to respond to the commonly prescribed androgen receptor signaling (ARS) inhibitors, but will have superior survival if treated with a taxane therapy. These findings were recently published in

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *